S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
Log in

ORIC Pharmaceuticals Stock Forecast, Price & News

-1.10 (-3.07 %)
(As of 02/24/2021 12:00 AM ET)
Today's Range
Now: $34.78
50-Day Range
MA: $33.02
52-Week Range
Now: $34.78
Volume165,635 shs
Average Volume282,273 shs
Market Capitalization$1.07 billion
P/E RatioN/A
Dividend YieldN/A
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ORIC
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Market Cap$1.07 billion
Next Earnings Date2/25/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.48 out of 5 stars

Medical Sector

457th out of 1,958 stocks

Pharmaceutical Preparations Industry

233rd out of 772 stocks

Analyst Opinion: 2.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
-1.10 (-3.07 %)
(As of 02/24/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ORIC News and Ratings via Email

Sign-up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

ORIC Pharmaceuticals (NASDAQ:ORIC) Frequently Asked Questions

Is ORIC Pharmaceuticals a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ORIC Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ORIC Pharmaceuticals stock.
View analyst ratings for ORIC Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than ORIC Pharmaceuticals?

Wall Street analysts have given ORIC Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ORIC Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ORIC Pharmaceuticals?

ORIC Pharmaceuticals saw a increase in short interest during the month of January. As of January 29th, there was short interest totaling 3,460,000 shares, an increase of 21.4% from the January 14th total of 2,850,000 shares. Based on an average daily volume of 352,000 shares, the short-interest ratio is presently 9.8 days. Approximately 12.3% of the company's stock are sold short.
View ORIC Pharmaceuticals' Short Interest

When is ORIC Pharmaceuticals' next earnings date?

ORIC Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for ORIC Pharmaceuticals

How were ORIC Pharmaceuticals' earnings last quarter?

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) released its earnings results on Thursday, November, 5th. The company reported ($0.84) EPS for the quarter, missing the Zacks' consensus estimate of ($0.39) by $0.45.
View ORIC Pharmaceuticals' earnings history

What price target have analysts set for ORIC?

7 equities research analysts have issued 12-month price objectives for ORIC Pharmaceuticals' shares. Their forecasts range from $34.00 to $52.00. On average, they anticipate ORIC Pharmaceuticals' share price to reach $43.43 in the next twelve months. This suggests a possible upside of 24.9% from the stock's current price.
View analysts' price targets for ORIC Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are ORIC Pharmaceuticals' key executives?

ORIC Pharmaceuticals' management team includes the following people:
  • Dr. Jacob M. Chacko M.B.A., M.D., Pres, CEO & Director (Age 42, Pay $672.13k)
  • Mr. Dominic G. Piscitelli CPA, M.B.A., CPA, Chief Financial Officer (Age 46, Pay $383.84k)
  • Dr. Pratik S. Multani, Chief Medical Officer (Age 54, Pay $535.16k)
  • Dr. Charles L. Sawyers B.A., BA, M.D., Ph.D., Co-Founder & Member of Scientific Advisory Board (Age 62)
  • Dr. Scott W. Lowe, Co-Founder & Member of Scientific Advisory Board
  • Dr. Lori Friedman Ph.D., Chief Scientific Officer (Age 57)
  • Dr. Christian V. Kuhlen J.D., M.D., Esq., Gen. Counsel (Age 48)
  • Dr. Edna Chow Maneval, Sr. VP of Clinical Devel. (Age 61)
  • Mr. Matthew Panuwat, Chief Bus. Officer (Age 44)

Who are some of ORIC Pharmaceuticals' key competitors?

What other stocks do shareholders of ORIC Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ORIC Pharmaceuticals investors own include Pfizer (PFE), Intel (INTC), CrowdStrike (CRWD), Valero Energy (VLO), Momo (MOMO), ONEOK (OKE), DocuSign (DOCU), Vaxart (VXRT), Delta Air Lines (DAL) and Datadog (DDOG).

When did ORIC Pharmaceuticals IPO?

(ORIC) raised $75 million in an initial public offering on Friday, April 24th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Citigroup, Jefferies and Guggenheim Securities served as the underwriters for the IPO.

What is ORIC Pharmaceuticals' stock symbol?

ORIC Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORIC."

Who are ORIC Pharmaceuticals' major shareholders?

ORIC Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.09%), Victory Capital Management Inc. (3.57%), Wells Fargo & Company MN (2.77%), Jennison Associates LLC (1.70%), Emerald Advisers LLC (1.69%) and Emerald Mutual Fund Advisers Trust (1.58%).
View institutional ownership trends for ORIC Pharmaceuticals

Which major investors are selling ORIC Pharmaceuticals stock?

ORIC stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., and State of Wisconsin Investment Board.
View insider buying and selling activity for ORIC Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying ORIC Pharmaceuticals stock?

ORIC stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Jennison Associates LLC, Wells Fargo & Company MN, Victory Capital Management Inc., Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Northern Trust Corp, and Alyeska Investment Group L.P..
View insider buying and selling activity for ORIC Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of ORIC Pharmaceuticals?

Shares of ORIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ORIC Pharmaceuticals' stock price today?

One share of ORIC stock can currently be purchased for approximately $34.78.

How much money does ORIC Pharmaceuticals make?

ORIC Pharmaceuticals has a market capitalization of $1.07 billion.

How many employees does ORIC Pharmaceuticals have?

ORIC Pharmaceuticals employs 60 workers across the globe.

What is ORIC Pharmaceuticals' official website?

The official website for ORIC Pharmaceuticals is www.oricpharma.com.

Where are ORIC Pharmaceuticals' headquarters?

ORIC Pharmaceuticals is headquartered at 240 E. GRAND AVE. 2ND FLOOR, SOUTH SAN FRANCISCO CA, 94080.

How can I contact ORIC Pharmaceuticals?

ORIC Pharmaceuticals' mailing address is 240 E. GRAND AVE. 2ND FLOOR, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-388-5600 or via email at [email protected]

This page was last updated on 2/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.